Advertisement

Ricerca in clinica e in laboratorio

, Volume 16, Issue 4, pp 563–568 | Cite as

Role of sialic acid in acquired dysfibrinogenemia associated with liver cirrhosis

  • María J. Narvaiza
  • Javier Fernández
  • Braulia Cuesta
  • José A. Páramo
  • Eduardo Rocha
Original Contributions
  • 22 Downloads

Summary

The possible existence of acquired dysfibrinogenemia was investigated in blood samples from 30 patients with liver cirrhosis, 15 newborns and 30 healthy control subjects. Alterations of thrombin time were found in newborns and in 14 cirrhotic patients; glucide fraction levels were measured in these subjects and an increase in sialic acid content was observed. Its functional role was studied by comparing thrombin time and electrophoretic mobility of purified and desialylated forms of fibrinogen. We observed a thrombin time normalization, which was initially prolonged upon the removal of the sialic acid. The anodic electrophoretic mobility underwent changes due to the removal of sialic acid.

Key-words

Acquired dysfibrinogenemia Fetal fibrinogen Fibrin formation Liver cirrhosis Sialic acid 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aminoff D.: Methods for the quantitative estimation ofN-acetylneuraminic acid and their application to hydrolysates of sialomucoids — Biochem. J.81, 384, 1961.PubMedGoogle Scholar
  2. 2.
    Aznar J., Tascon A., Aznar J. A., Rodriguez-Inerba M.: Técnica rápida para la valoración del fibrinógeno por el método de precipitación por calor — Rev. Diagn. biol. (Madr.)22, 373, 1973.Google Scholar
  3. 3.
    Barr R. D., Allardyce M., Brunt P. W., McPhie J. L.: Dysfibrinogenemia and liver cell growth — J. clin. Pathol.31, 89, 1978.PubMedCrossRefGoogle Scholar
  4. 4.
    Barr R. D., Ouna N., Simpson J. C., Bagshawe A. F.: Dysfibrinogenemia and primary hepatocellular carcinoma — Quart. J. Med.45, 647, 1976.PubMedGoogle Scholar
  5. 5.
    Bloom A. L.: Intravascular coagulation and liver — Brit. J. Haematol.30, 1, 1975.CrossRefGoogle Scholar
  6. 6.
    Bohn H., Haupt H.: Eine quantitative Bestimmung von Faktor XIII mit Anti-Faktor-XIII-Serum — Thrombos. Diathes. haemorrh. (Stuttg.)19, 309, 1968.Google Scholar
  7. 7.
    Cessi C., Piliego F.: The determination of amino sugars in the presence of amino acids and glucose — Biochem. J.77, 508, 1960.PubMedGoogle Scholar
  8. 8.
    Clauss A.: Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens — Acta haematol. (Basel)17, 237, 1957.CrossRefGoogle Scholar
  9. 9.
    Grabar P., Williams C. A.: Méthode immunoélectrophorétique d’analyse de mélanges de substances antigèniques — Biochim. biophys. Acta (Amst.)17, 67, 1955.CrossRefGoogle Scholar
  10. 10.
    Gralnick H., Givelber H., Abrams E.: Dysfibrinogenemia associated with hepatoma: increased carbohydrate content of fibrinogen molecule — New Engl. J. Med.299, 221, 1978.PubMedGoogle Scholar
  11. 11.
    Jim R. T. S.: A study of the plasma thrombin — J. Lab. clin. Med.50, 45, 1957.PubMedGoogle Scholar
  12. 12.
    Kwan S. W., Fuller G. H.: Immunochemical characterization of fibrinogen induction in rat liver — Biochim. biophys. Acta (Amst.)475, 659, 1977.Google Scholar
  13. 13.
    Lane D. A., Scully M. F., Thomas D. P., Kakkar V. V., Woolf I. L., Williams R.: Acquired dysfibrinogenaemia in acute and chronic liver disease — Brit. J. Haematol.35, 301, 1977.CrossRefGoogle Scholar
  14. 14.
    Laurell C.-B.: Electroimmunoassay — Scand. J. clin. Lab. Invest.29 (Suppl. 21), 124, 1972.Google Scholar
  15. 15.
    Martinez J., Palascak J., Kwasniak D.: Abnormal sialic acid content of the dysfibrinogenemia associated with liver disease — J. clin. Invest.61, 535, 1978.PubMedCrossRefGoogle Scholar
  16. 16.
    Merskey C., Lalezari P., Johnson A. J.: A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum — Proc. Soc. exp. Biol. (N.Y.)131, 871, 1969.Google Scholar
  17. 17.
    Mester L., Szabados L.: Structure défectueuse et biosynthèse des fractions glucidiques dans les variantes pathologiques du fibrinogène — Nouv. Rev. franç. Hématol.10, 679, 1970.Google Scholar
  18. 18.
    Narvaiza M. J.: Contribución al estudio de las alteraciones funcionales y físicoquímicas del fibrinógeno en la cirrosis hepática. Tesis doctoral, Universidad de Navarra, 1979.Google Scholar
  19. 19.
    Palascak J., Martinez J.: Dysfibrinogenemia associated with liver disease — J. clin. Invest.60, 89, 1977.PubMedCrossRefGoogle Scholar
  20. 20.
    Ratnoff O. D., Menzie C.: A new method for the determination of fibrinogen in small samples of plasma — J. Lab. clin. Med.37, 316, 1951.PubMedGoogle Scholar
  21. 21.
    Roberts H. R., Cederbaum A. I.: The liver and blood coagulation: physiology and pathology — Gastroenterology63, 297, 1972.PubMedGoogle Scholar
  22. 22.
    Soria J., Soria C., Durand G., Feger J.: Electrofocalisation de fibrinogènes anormaux en gel de polyacrylamide — Ann. Biol. clin.30, 161, 1972.Google Scholar
  23. 23.
    Straub P. W., Funk C.: The Reptilase time in presence of fibrinogen degradation products — Scand. J. Haematol.13 (Suppl.), 257, 1971.Google Scholar

Copyright information

© Casa Editrice «Il Ponte» 1986

Authors and Affiliations

  • María J. Narvaiza
    • 1
  • Javier Fernández
    • 1
  • Braulia Cuesta
    • 1
  • José A. Páramo
    • 1
  • Eduardo Rocha
    • 1
  1. 1.Servicio de Hematología Clínica UniversitariaUniversidad de NavarraPamplonaSpain

Personalised recommendations